Prescient Therapeutics demystifies OmniCAR’s ‘on-demand tumour killing’ capabilities
Prescient Therapeutics’ next-generation CAR-T platform OmniCAR has delivered overwhelmingly positive results in recent pre-clinical studies...
Prescient Therapeutics’ next-generation CAR-T platform OmniCAR has delivered overwhelmingly positive results in recent pre-clinical studies...
Biotech company Prescient Therapeutics has given investors a glimpse into the progress of it’s next-generation...
Australian biotech company Prescient Therapeutics has achieved numerous milestones in the past financial year as...
Prescient Therapeutics has announced that a global expert in brain cancer, Professor Donald M. O’Rourke,...
CAR-T therapies have proven to be revolutionary treatments for cancer, but their high costs have...
Australian biotech company Prescient Therapeutics has successfully finished a round of safety testing on its...
The US Food and Drug Administration has assigned a fast track designation to a new...
Shares in biotech company, Prescient Therapeutics, have proved buoyant this week after initial immunogenicity testing...
The terrible news this week that Tmunity Therapeutics, a clinical stage biotherapeutics company, has halted...
Australia’s medical community has welcomed a new ‘patent box’ tax regime designed to encourage further...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.